559 related articles for article (PubMed ID: 27022039)
1. Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue.
Herrmann J; Yang EH; Iliescu CA; Cilingiroglu M; Charitakis K; Hakeem A; Toutouzas K; Leesar MA; Grines CL; Marmagkiolis K
Circulation; 2016 Mar; 133(13):1272-89. PubMed ID: 27022039
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine Kinase Inhibitors and Vascular Toxicity: Impetus for a Classification System?
Herrmann J
Curr Oncol Rep; 2016 Jun; 18(6):33. PubMed ID: 27099141
[TBL] [Abstract][Full Text] [Related]
3. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Zambelli A; Della Porta MG; Eleuteri E; De Giuli L; Catalano O; Tondini C; Riccardi A
Breast; 2011 Apr; 20(2):176-83. PubMed ID: 21146409
[TBL] [Abstract][Full Text] [Related]
4. Cardioncology: state of the heart.
Todaro MC; Oreto L; Qamar R; Paterick TE; Carerj S; Khandheria BK
Int J Cardiol; 2013 Sep; 168(2):680-7. PubMed ID: 23639459
[TBL] [Abstract][Full Text] [Related]
5. Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management.
Layoun ME; Wickramasinghe CD; Peralta MV; Yang EH
Curr Oncol Rep; 2016 Jun; 18(6):35. PubMed ID: 27113369
[TBL] [Abstract][Full Text] [Related]
6. Cardiotoxicity of molecularly targeted agents.
Hedhli N; Russell KS
Curr Cardiol Rev; 2011 Nov; 7(4):221-33. PubMed ID: 22758623
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms for vascular complications of targeted cancer therapies.
Gopal S; Miller KB; Jaffe IZ
Clin Sci (Lond); 2016 Oct; 130(20):1763-79. PubMed ID: 27612952
[TBL] [Abstract][Full Text] [Related]
8. [Onco-Cardiology - From the Standpoint of Cardiology].
Shioyama W
Gan To Kagaku Ryoho; 2017 Dec; 44(13):2052-2057. PubMed ID: 29361616
[TBL] [Abstract][Full Text] [Related]
9. Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina.
Stewart T; Pavlakis N; Ward M
Intern Med J; 2010 Apr; 40(4):303-7. PubMed ID: 20529041
[TBL] [Abstract][Full Text] [Related]
10. Curing Cancer, Saving the Heart: A Challenge That Cardioncology Should Not Miss.
Cardinale D; Biasillo G; Cipolla CM
Curr Cardiol Rep; 2016 Jun; 18(6):51. PubMed ID: 27108361
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Toxicities with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of 77 Randomized Controlled Trials.
Li J; Gu J
Clin Drug Investig; 2018 Dec; 38(12):1109-1123. PubMed ID: 30327999
[TBL] [Abstract][Full Text] [Related]
12. Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy.
Virani SA; Dent S; Brezden-Masley C; Clarke B; Davis MK; Jassal DS; Johnson C; Lemieux J; Paterson I; Sebag IA; Simmons C; Sulpher J; Thain K; Thavendiranathan P; Wentzell JR; Wurtele N; Côté MA; Fine NM; Haddad H; Hayley BD; Hopkins S; Joy AA; Rayson D; Stadnick E; Straatman L
Can J Cardiol; 2016 Jul; 32(7):831-41. PubMed ID: 27343741
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular toxic effects of targeted cancer therapy.
Tajiri K; Aonuma K; Sekine I
Jpn J Clin Oncol; 2017 Sep; 47(9):779-785. PubMed ID: 28531278
[TBL] [Abstract][Full Text] [Related]
14. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management.
Curigliano G; Cardinale D; Dent S; Criscitiello C; Aseyev O; Lenihan D; Cipolla CM
CA Cancer J Clin; 2016 Jul; 66(4):309-25. PubMed ID: 26919165
[TBL] [Abstract][Full Text] [Related]
15. The importance of clinical grading of heart failure and other cardiac toxicities during chemotherapy: updating the common terminology criteria for clinical trial reporting.
Hossain A; Chen A; Ivy P; Lenihan DJ; Kaltman J; Taddei-Peters W; Remick SC
Heart Fail Clin; 2011 Jul; 7(3):373-84. PubMed ID: 21749889
[TBL] [Abstract][Full Text] [Related]
16. Cardio-Oncology: An Update on Cardiotoxicity of Cancer-Related Treatment.
Lenneman CG; Sawyer DB
Circ Res; 2016 Mar; 118(6):1008-20. PubMed ID: 26987914
[TBL] [Abstract][Full Text] [Related]
17. Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors.
Maurea N; Coppola C; Piscopo G; Galletta F; Riccio G; Esposito E; De Lorenzo C; De Laurentiis M; Spallarossa P; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1():S19-26. PubMed ID: 27183521
[TBL] [Abstract][Full Text] [Related]
18. Cancer treatment-induced cardiotoxicity: a cardiac stem cell disease?
Prezioso L; Tanzi S; Galaverna F; Frati C; Testa B; Savi M; Graiani G; Lagrasta C; Cavalli S; Galati S; Madeddu D; Lodi Rizzini E; Ferraro F; Musso E; Stilli D; Urbanek K; Piegari E; De Angelis A; Maseri A; Rossi F; Quaini E; Quaini F
Cardiovasc Hematol Agents Med Chem; 2010 Jan; 8(1):55-75. PubMed ID: 20210776
[TBL] [Abstract][Full Text] [Related]
19. Roles of pharmacogenomics in non-anthracycline antineoplastic-induced cardiovascular toxicities: A systematic review and meta-analysis of genotypes effect.
Leong SL; Chaiyakunapruk N; Tassaneeyakul W; Arunmanakul P; Nathisuwan S; Lee SWH
Int J Cardiol; 2019 Apr; 280():190-197. PubMed ID: 30594345
[TBL] [Abstract][Full Text] [Related]
20. Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors.
Maurea N; Coppola C; Piscopo G; Galletta F; Riccio G; Esposito E; De Lorenzo C; De Laurentiis M; Spallarossa P; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e19-e26. PubMed ID: 27755239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
